Holen Sie sich die Stockscreener-App
2.75
2.91%
-0.0528
Biorestorative Therapies Inc Aktie (BRTX) Neueste Nachrichten
BioRestorative Therapies, Inc. Earnings and Revenue – FWB:9OF0 - TradingView
BioRestorative Therapies Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
Biorestorative Therapies To Carry Out 1-for-20 Reverse Stock Split On September 8th, 2026 - Moomoo
BioRestorative Therapies Announces Reverse Stock Split - Ortho Spine News
BioRestorative Therapies Announces 1-for-20 Reverse Stock Split - TipRanks
Biorestorative Therapies Announces Reverse Stock Split - TradingView
BioRestorative Therapies: Board Approves 1-For-20 Reverse Split >BRTX - Moomoo
BioRestorative Therapies Names New Interim CEO and CFO - Minichart
BioRestorative Therapies Inc (BRTX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
BioRestorative Therapies Inc (BRTX) Key Financial Ratios – Valuation, Profitability & More - Value Research
BioRestorative Therapies Inc (BRTX) Peer Comparison – Compare with Others - Value Research
BRTX Q1 2026 Earnings: Narrower Net Loss Beats Estimates as Pipeline AdvancesQuarterly Earnings Report - vinanet.vn
BioRestorative Therapies Faces Nasdaq Delinquency Notice Risk - TipRanks
BioRestorative Therapies Received Notice of Noncompliance - TradingView
BioRestorative (BRTX) Chart: Slides 0.98% to $0.21 for the Current Session; Price Levels: Price Remains Between $0.20 Support and $0.22 Resistance in the Latest ReadingFibonacci Retracement - vinanet.vn
BioRestorative (BRTX) Move: Retreats 2.40% to $0.22 for the Current Session; Range Check: the Current Price Sits Inside the Supplied Technical Range in the Latest ReadingVolume Spike Alerts - vinanet.vn
BioRestorative Therapies Halts ExoCR and BioX Shipments - TipRanks
MSN Money - MSN
BioRestorative Therapies (NASDAQ:BRTX): Why Is Cell-Therapy Development And Manufacturing Readiness in Focus Today? - Kalkine Media
BioRestorative Therapies (NASDAQ:BRTX): Why Is Cell-Therapy Development And Funding in Focus Today? - Kalkine Media
BRTX Q2'26 Earnings: EPS estimate is (0.10) USD - TradingView
BioRestorative Therapies (BRTX) Holds Near $0.23 as Modest Gains Build on Thin VolumeFundamentals - dars.gov.et
Form 8K BioRestorative Therapies Inc For: 14 August By Investing.com - Investing.com Nigeria
BioRestorative Therapies suspends shipments of ExoCR and BioX products for review - Investing.com Australia
BioRestorative Therapies Delays Quarterly SEC Filing - TipRanks
Biorestorative Therapies Suspends All Orders, Shipments Of Exocr, Biox Biocosmeceutical Product Lines Effective Immediately, On Aug 7 - TradingView
BioRestorative Therapies (BRTX) delays Q2 10-Q amid losses and going-concern risk - Stock Titan
BioRestorative Therapies, Inc. Suspends All Orders And Shipments Of Biocosmeceutical Product Lines - marketscreener.com
BRTX Q2'26 Earnings: revenue estimate is 600.00K USD - TradingView
BRTX Q1 2026 Earnings: Narrower-Than-Expected Loss Delivers 41% EPS SurpriseRevenue Guidance Update - vinanet.vn
BioRestorative Therapies Inc (BRTX) Stock News Today - TradingKey
BioRestorative Therapies (BRTX) Edges Lower, Holds $0.20 Support as Price Action TightensFloat Adjusted Cap - dars.gov.et
BioRestorative Therapies (BRTX) investor Alta Partners reports 4.99% ownership cap - Stock Titan
BRTX Q1 2026 Earnings: Loss Beats Estimates by 41.18% While Shares Fall 9.22%Revenue Recognition Risk - vinanet.vn
BioRestorative Therapies (BRTX) reports director Esha Randhawa’s insider status - Stock Titan
BioRestorative Therapies Inc - TradingKey
BioRestorative Therapies Inc (BRTX) Balance Sheet - TradingKey
BioRestorative Therapies Inc (BRTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BioRestorative Therapies Inc (BRTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
BioRestorative Therapies Inc (BRTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BioRestorative Therapies Inc (BRTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BRTX|BioRestorative Therapies Inc|Price:0.219|Chg%:+0.018 - TradingKey
BioRestorative Therapies Inc (BRTX) Cash Flow - TradingKey
BioRestorative Therapies Inc (BRTX) Income Statement - tradingkey.com
BRTX|BioRestorative Therapies Inc|Price:0.270|Chg%:-0.007 - TradingKey
BioRestorative Therapies Inc (BRTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BRTX|BioRestorative Therapies Inc|Price:0.282|Chg%:-0.008 - TradingKey
BRTX|BioRestorative Therapies Inc|Price:0.226|Chg%:+0.006 - TradingKey
BioRestorative Therapies (BRTX) Slides 7% – Testing Critical Support at $0.28Institutional Sentiment - vinanet.vn
BioRestorative Therapies, Inc. Revenue Breakdown – GETTEX:9OF - TradingView
BRTX Q1 2026 Earnings: Narrower Loss Exceeds Expectations Amid Pipeline ProgressEarnings Yield Analysis - vinanet.vn
Biorestorative Therapies Company Profile & Introduction - Moomoo
BRTX Q1 2026 Earnings: EPS Surpasses Estimates Despite No Revenue, Stock SlipsForward EPS Estimate - vinanet.vn
BioRestorative Therapies (BRTX) Q1 2026 Earnings: Narrower Loss Beats Estimates as Company Advances PipelineAnnual Financial Report - dars.gov.et
BioRestorative Therapies Announces Amendments to Executive Employment Agreements in July 2026 - Minichart
Leadership shake-up at Biorestorative Therapies (NASDAQ: BRTX) and new CEO - Stock Titan
BioRestorative Therapies, Inc. Announces CFO Changes, Effective July 13, 2026 - marketscreener.com
BRTX Q1 2026 Earnings: EPS Surpasses Estimates Despite No RevenuePerformance Review - vinanet.vn
BioRestorative Therapies (BRTX) Holds Steady Near Support Zone Amid Quiet TradingDynamic Hedging - dars.gov.et
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
BioRestorative Therapies (BRTX) Slips 2.55% as Stock Approaches Crucial Support ZoneETF NAV Deviation - dars.gov.et
Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX) - AOL.com
Price to book forward of BioRestorative Therapies, Inc. – GETTEX:9OF - TradingView
0.29%
4.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):